AC Immune SA (ACIU) Fair Value 2026

ACIU · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.6 /10

32 fundamental signals · 10 models active

Value Trap Risk

SAFE (20/100)

Quick Summary — As of 2026-07-13, AC Immune SA (ACIU) trades at $2.45, approximately 59% below CirclFi’s Bayesian DCF fair value of $5.95. QOC: 5.6/10. Value Trap Risk: 20/100 (SAFE). 10/13 models active.

Key Facts

Ticker
ACIU
Price
$2.45
Quality Score
5.6/10
Value Trap Risk
20/100
Models Active
10/13
Last Updated
Strength: Bayesian DCF suggests +142.7% upside with 56% confidence
Risk: Limited model coverage (10/13) may reduce confidence

Valuation Matrix

10 Intrinsic Value Models vs. Current Price ($2.45)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
High Conviction
$5.95 +142.7%
CUCE Ensemble
Low Conviction
$3.85 +57.1%
First Chicago
Medium Conviction
$0.45 -81.6%
ML-RIV
Medium Conviction
$0.09 -96.5%

Unlock the Full Matrix

Access 6 additional models including Dynamic NAV, PWERM, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 10 Models →

Cancel anytime · No contracts · Instant access

What Is AC Immune SA (ACIU) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, AC Immune SA presents a highly debated valuation profile at its current price of $2.45. The composite intrinsic value is estimated at $2.66 (+8.6% average upside), masking a wide model spread between the 4 bullish models and 5 bearish models. Model dispersion is worth noting: RCMH-DCF targets $9.74 (+297.6%), versus ML-RIV at $0.09 (-96.5%). This +394.0% range highlights the importance of multi-model analysis rather than relying on any single methodology.

What Do the Models Say About ACIU?

10 of 13 models are currently active for ACIU. Of these, 5 models suggest upside while 5 models suggest overvaluation. The Bayesian DCF estimates ACIU's intrinsic value at $5.95, implying +142.7% upside from the current price. See which stocks rank higher →

How Does ACIU Rank in Biotechnology?

Among 62 Biotechnology stocks, ACIU ranks #20 by Quality of Company score. CirclFi's QOC score of 5.6/10 evaluates 32 fundamental signals. A score of 5.6 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

The Biotechnology sector introduces analytical considerations specific to biotechnology enterprise businesses. For AC Immune SA, metrics like R&D burn rate provide important context that general-purpose valuation models may underweight.

Is ACIU a Value Trap?

CirclFi's Value Trap algorithm assigns ACIU a score of 20/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

10 of 13 models are active for AC Immune SA. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, AC Immune SA scores 5.6 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

The gap between the most bullish and bearish model spans +394.0% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ACIU valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across ACIU's 10 active models, average confidence is 30%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy AC Immune SA Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

8 related Biotechnology stocks with 13-model coverage

Read investment analysis: ADMA · ACAD · ALNY · ACRS · ABCL

See all Biotechnology stocks ranked →

Frequently Asked Questions About AC Immune SA

What is AC Immune SA's intrinsic value in 2026?

Based on CirclFi's 13-model analysis, AC Immune SA (ACIU) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $5.95. The Quality of Company score is 5.6/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ACIU overvalued or undervalued right now?

At $2.45, 5 of 10 active models suggest ACIU may be undervalued, while 5 indicate potential overvaluation. The assessment depends on which methodology best fits AC Immune SA's business model in Biotechnology.

What does a Quality of Company score of 5.6 mean for ACIU?

AC Immune SA's QOC of 5.6/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on ACIU?

CirclFi analyzes ACIU with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 10 of 13 are active for this stock. Read the full methodology →

Is ACIU a value trap in 2026?

AC Immune SA's Value Trap score is 20/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 10 mathematical frameworks give you clarity on ACIU.

Unlock All 10 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access